D-ribose

• uric acid

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• lactate

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• glucose

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• ammonia

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• average power

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• fatigue index

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• peak power, average power, torque, fatigue index, lactate, ammonia, glucose and uric acid across two 30-s Wingate sprints

  no effect

  Not recorded as a finding: the supporting sentence never names the compound

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid.

  PMID:12660407 · one of two readings recorded this

• peak power, average power, total work output and fatigue index on two 30-s Wingate tests; lactate, ammonia, glucose, uric acid

  no effect, no significant interactions in peak power, average power, torque, fatigue index or metabolic markers

  Not recorded as a finding: the supporting sentence never names the compound

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid.

  PMID:12660407 · one of two readings recorded this

• peak power

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• torque

  no effect, n = 19

  No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid

  PMID:12660407 · one of two readings recorded this

• total work output (interaction)

  p = 0.04, n = 19

  Results revealed a significant interaction (p =.04) in total work output

  PMID:12660407 · one of two readings recorded this

• work output, second post-supplementation sprint

  n = 19

  work significantly declined (-18 +/- 51 J) during the second post-supplementation sprint in the P group while being maintained in the R group (-0.0 +/- 31 J)

  PMID:12660407 · one of two readings recorded this

• atrial contribution to left ventricular filling

  increases, p = 0.02, n = 15

  The administration of D-ribose resulted in an enhancement of atrial contribution to left ventricular filling (40+/-11 vs. 45+/-9%, P=0.02)

  PMID:14607200 · one of two readings recorded this

• E wave deceleration

  decreases, p = 0.002, n = 15

  a shortened E wave deceleration (235+/-64 vs. 196+/-42, P=0.002)

  PMID:14607200 · one of two readings recorded this

• echocardiographic changes and quality of life on placebo

  no effect, n = 15

  In comparison, placebo did not result in any significant echocardiographic changes or in quality of life

  PMID:14607200 · one of two readings recorded this

• left atrial dimension

  decreases, p = 0.02, n = 15

  a smaller left atrial dimension (54+/-20 vs. 47+/-18 ml, P=0.02)

  PMID:14607200 · one of two readings recorded this

• quality of life by the SF-36 questionnaire; echocardiographic atrial contribution to LV filling, left atrial volume and E wave deceleration

  increases, quality of life 417+/-118 vs. 467+/-128 on D-ribose

  Not recorded as a finding: the result compares a group with itself, not with a control

  Further, D-ribose also demonstrated a significant improvement of the patient's quality of life (417+/-118 vs. 467+/-128, P< or =0.01).

  PMID:14607200 · one of two readings recorded this

• quality of life on the SF-36 questionnaire; echocardiographic atrial contribution to filling, left atrial dimension and E wave deceleration

  increases, 417+/-118 versus 467+/-128 on quality of life

  Not recorded as a finding: the result compares a group with itself, not with a control

  Further, D-ribose also demonstrated a significant improvement of the patient's quality of life (417+/-118 vs. 467+/-128, P< or =0.01).

  PMID:14607200 · one of two readings recorded this

• quality of life

  increases, p = 0.01, n = 15

  D-ribose also demonstrated a significant improvement of the patient's quality of life (417+/-118 vs. 467+/-128, P< or =0.01)

  PMID:14607200 · one of two readings recorded this

• mean and peak power output during an exercise test 72 h after a week of intense sprint training; muscle ATP and plasma hypoxanthine

  no effect

  Not recorded as a finding: the paper never states the instrument the node requires

  Mean and peak power outputs during the test performed at 72 h were similar (P > 0.05) in Pla and Rib.

  PMID:14660478 · one of two readings recorded this

• mean and peak power output during test at 72 h

  no effect, p = 0.05

  Mean and peak power outputs during the test performed at 72 h were similar (P > 0.05) in Pla and Rib

  PMID:14660478 · one of two readings recorded this

• muscle ATP at 5 h and 24 h after exercise vs pretraining

  decreases, p = 0.05

  In both Pla and Rib, muscle ATP levels at 5 and 24 h after the exercise were still lower (P < 0.05) than pretraining

  PMID:14660478 · one of two readings recorded this

• muscle ATP at 72 h, Rib vs Pla

  increases, p = 0.05

  and higher (P < 0.05) in Rib than in Pla

  PMID:14660478 · one of two readings recorded this

• muscle ATP at 72 h vs pretraining

  decreases, p = 0.05

  but still lower (P < 0.05) in Pla (21.1 +/- 0.5 vs. 26.0 +/- 0.2 mmol/kg dry wt)

  PMID:14660478 · one of two readings recorded this

• muscle ATP at 72 h vs pretraining

  no effect, p = 0.05

  After 72 h, muscle ATP was similar (P > 0.05) to pretraining in Rib (24.6 +/- 0.6 vs. 26.2 +/- 0.2 mmol/kg dry wt)

  PMID:14660478 · one of two readings recorded this

• muscle ATP, biopsy, 72 h after the last training session

  increases, Rib 24.6 vs 26.2 mmol/kg dw pretraining; Pla 21.1 vs 26.0; higher in Rib than Pla

  Not recorded as a finding: no outcome node for muscle ATP concentration

  After 72 h, muscle ATP was similar (P > 0.05) to pretraining in Rib (24.6 +/- 0.6 vs. 26.2 +/- 0.2 mmol/kg dry wt) but still lower (P < 0.05) in Pla (21.1 +/- 0.5 vs. 26.0 +/- 0.2 mmol/kg dry wt) and higher (P < 0.05) in Rib than in Pla.

  PMID:14660478 · one of two readings recorded this

• muscle ATP immediately after last training session vs pretraining

  decreases, p = 0.05

  Immediately after the last training session, muscle ATP was lowered (P < 0.05) by 25 +/- 2 and 22 +/- 3% in Pla and Rib, respectively

  PMID:14660478 · one of two readings recorded this

• muscle ATP immediately after last training session vs pretraining

  decreases, p = 0.05

  Immediately after the last training session, muscle ATP was lowered (P < 0.05) by 25 +/- 2 and 22 +/- 3% in Pla and Rib, respectively

  PMID:14660478 · one of two readings recorded this

• plasma hypoxanthine after test at 72 h

  increases, p = 0.05

  Plasma hypoxanthine levels after the test performed at 72 h were higher (P < 0.05) in Rib compared with Pla

  PMID:14660478 · one of two readings recorded this

• plasma hypoxanthine after the test at 72 h

  increases, higher in Rib compared with Pla

  Not recorded as a finding: no outcome node for plasma hypoxanthine

  Plasma hypoxanthine levels after the test performed at 72 h were higher (P < 0.05) in Rib compared with Pla.

  PMID:14660478 · one of two readings recorded this

• 2000-m rowing time-trial improvement at 8 weeks, ribose versus dextrose (10 g each in 8 oz water)

  median improvement 15.2 s dextrose vs 5.2 s ribose, p = 0.031

  Not recorded as a finding: the comparison was against another active treatment

  In the time trials, the dextrose group showed significantly more improvement at 8 weeks than the ribose group (median, 15.2 vs. 5.2 s; P = 0.031).

  PMID:16377979 · one of two readings recorded this

• 2000-m rowing time trial, improvement at 8 weeks

  median improvement 15.2 s with dextrose versus 5.2 s with ribose, p = 0.031

  Not recorded as a finding: the comparison was against another active treatment

  In the time trials, the dextrose group showed significantly more improvement at 8 weeks than the ribose group (median, 15.2 vs. 5.2 s; P = 0.031).

  PMID:16377979 · one of two readings recorded this

• 2000-m time trial improvement

  p = 0.031

  the dextrose group showed significantly more improvement at 8 weeks than the ribose group (median, 15.2 vs. 5.2 s; P = 0.031)

  PMID:16377979 · one of two readings recorded this

• anaerobic capacity over 5 x 30 s sprint tests and capillary adenine nucleotide breakdown markers

  no effect

  Not recorded as a finding: the intervention held more than the compound

  D-ribose supplementation has no impact on anaerobic exercise capacity and metabolic markers after high-intensity cycling exercise.

  PMID:16521849 · one of two readings recorded this

• anaerobic capacity over 5 x 30 s tests and capillary adenine nucleotide breakdown markers

  no effect, no significant interactions for any performance or blood variable

  Not recorded as a finding: this platform holds no node for the endpoint

  No significant interactions were observed for any performance or blood variables.

  PMID:16521849 · one of two readings recorded this

• anaerobic exercise capacity and metabolic markers

  no effect, n = 12

  D-ribose supplementation has no impact on anaerobic exercise capacity and metabolic markers after high-intensity cycling exercise

  PMID:16521849 · one of two readings recorded this

• performance and blood variables (interactions)

  no effect, n = 12

  No significant interactions were observed for any performance or blood variables

  PMID:16521849 · one of two readings recorded this

• Mean power, Wingate tests

  no effect, p = 0.05

  Repeated-measures analysis of variance (p > 0.05) found no significant differences between ribose and placebo

  PMID:16937963 · one of two readings recorded this

• peak power, mean power and percent decrease in power across three 30-second Wingate tests

  no effect

  Not recorded as a finding: the supporting sentence never names the compound

  Repeated-measures analysis of variance (p > 0.05) found no significant differences between ribose and placebo.

  PMID:16937963 · one of two readings recorded this

• peak power, mean power and percent decrease in power over three 30-second Wingate tests

  no effect

  Not recorded as a finding: no estimate is reported anywhere

  Repeated-measures analysis of variance (p > 0.05) found no significant differences between ribose and placebo.

  PMID:16937963 · one of two readings recorded this

• Peak power, Wingate tests

  no effect, p = 0.05

  Repeated-measures analysis of variance (p > 0.05) found no significant differences between ribose and placebo

  PMID:16937963 · one of two readings recorded this

• Percent decrease in power, Wingate tests

  no effect, p = 0.05

  Repeated-measures analysis of variance (p > 0.05) found no significant differences between ribose and placebo

  PMID:16937963 · one of two readings recorded this

• Mental fatigue outcomes (task performance, subjective fatigue, plasma branched-chain amino acids)

  no effect

  Administration of D-ribose had no effect

  PMID:18178380 · one of two readings recorded this

• mental task performance (Uchida-Kraepelin test, advanced trail-making test), subjective fatigue, motivation, sleepiness and plasma branched-chain amino acids after fatigue-inducing mental tasks

  no effect

  Not recorded as a finding: no estimate is reported anywhere

  Administration of D-ribose had no effect.

  PMID:18178380 · one of two readings recorded this

• plasma branched-chain amino acid levels after 30-min Uchida-Kraepelin and advanced trail-making mental fatigue tasks

  no effect

  Not recorded as a finding: this platform holds no node for the endpoint

  Administration of D-ribose had no effect.

  PMID:18178380 · one of two readings recorded this

• Plasma branched-chain amino acid levels after fatigue-inducing tasks

  decreases

  plasma branched-chain amino acid levels in the caffeine group were lower than those of the placebo group

  PMID:18178380 · one of two readings recorded this

• Subjective perception of fatigue, motivation, or sleepiness after fatigue-inducing tasks

  no effect

  although subjective perception of fatigue, motivation, or sleepiness was not significantly different

  PMID:18178380 · one of two readings recorded this

• Task performance during fatigue-inducing mental tasks

  increases

  During the tasks, the task performance of the caffeine group was better than that of the placebo group

  PMID:18178380 · one of two readings recorded this

• Body weight, change from PRE to POST

  decreases

  Body weight (BW; 1.8% decrease CON; 1.3% decrease TEST from PRE to POST)

  PMID:22692117 · one of two readings recorded this

• Body weight, TEST versus CON

  no effect

  Overall, even though the TEST drink did not augment BW, V(O2)peak, or TTE beyond carbohydrates alone

  PMID:22692117 · one of two readings recorded this

• Fat-free mass, change from PRE to POST

  decreases

  FFM (0.1% decrease CON; 0.6% decrease TEST)

  PMID:22692117 · one of two readings recorded this

• Fat-free mass, percent increase PRE to MID3

  increases, p = 0.05

  Percent decreases in %fat from PRE to MID3 and percent increases in FFM from PRE to MID3 and MID6 were greater (p ≤ 0.05) for TEST than CON

  PMID:22692117 · one of two readings recorded this

• Fat-free mass, percent increase PRE to MID6

  increases, p = 0.05

  Percent decreases in %fat from PRE to MID3 and percent increases in FFM from PRE to MID3 and MID6 were greater (p ≤ 0.05) for TEST than CON

  PMID:22692117 · one of two readings recorded this

• percent body fat and fat-free mass during 8 weeks of cycle training; body weight, VO2peak, time to exhaustion at 90% VO2peak

  increases, percent increases in FFM from PRE to MID3 and MID6 greater for TEST than CON

  Not recorded as a finding: the intervention held more than the compound

  Percent decreases in %fat from PRE to MID3 and percent increases in FFM from PRE to MID3 and MID6 were greater (p ≤ 0.05) for TEST than CON.

  PMID:22692117 · one of two readings recorded this

• Percent body fat, change from PRE to POST

  decreases

  %fat (5.5% decrease CON; 3.9% decrease TEST)

  PMID:22692117 · one of two readings recorded this

• Percent body fat, percent decrease PRE to MID3

  decreases, p = 0.05

  Percent decreases in %fat from PRE to MID3 and percent increases in FFM from PRE to MID3 and MID6 were greater (p ≤ 0.05) for TEST than CON

  PMID:22692117 · one of two readings recorded this

• Time to exhaustion at 90% VO2peak, change from PRE to POST

  increases

  TTE (239.1% increase CON; 377.3% increase TEST)

  PMID:22692117 · one of two readings recorded this

• Time to exhaustion, TEST versus CON

  no effect

  Overall, even though the TEST drink did not augment BW, V(O2)peak, or TTE beyond carbohydrates alone

  PMID:22692117 · one of two readings recorded this

• VO2peak, change from PRE to POST

  increases

  V(O2)peak (19.1% increase CON; 15.8% increase TEST)

  PMID:22692117 · one of two readings recorded this

• VO2peak, TEST versus CON

  no effect

  Overall, even though the TEST drink did not augment BW, V(O2)peak, or TTE beyond carbohydrates alone

  PMID:22692117 · one of two readings recorded this

• overall survival

  no effect, n = 426

  HR 1.05, 95% CI 0.79 to 1.39; 426 participants

  PMID:25991068 · one of two readings recorded this

• progression-free survival

  increases, n = 426

  hazard ratio (HR) 0.42, 95% confidence interval (CI) 0.29 to 0.60; 426 participants

  PMID:25991068 · one of two readings recorded this

• severe adverse events (G3/4) during maintenance phase

  increases, n = 385

  risk ratio (RR) 1.74, 95% CI 1.22 to 2.49; 385 participants

  PMID:25991068 · one of two readings recorded this

• grade >=3 abdominal pain

  no effect, p = 0.13

  Abdominal pain | 5 | 350/265 | 0.48[0.18,1.25] | 0.13 | 0.00 | 0.86

  PMID:26399274 · one of two readings recorded this

• grade >=3 anaemia

  no effect, p = 0.25

  Anaemia | 8 | 703/609 | 1.45[0.77,2.75] | 0.25 | 49.00 | 0.06

  PMID:26399274 · one of two readings recorded this

• grade >=3 anorexia

  no effect, p = 0.67

  Anorexia | 2 | 72/66 | 0.67[0.11,4.17] | 0.67 | 0.00 | 0.61

  PMID:26399274 · one of two readings recorded this

• grade >=3 arthralgia

  no effect, p = 0.34

  Arthralgia | 2 | 193/187 | 2.96[0.31,28.17] | 0.34 | 0.00 | 0.97

  PMID:26399274 · one of two readings recorded this

• grade >=3 asthenia

  decreases, p = 0.02

  Asthenia | 3 | 278/199 | 0.34[0.14,0.82] | 0.02 | 2.00 | 0.36

  PMID:26399274 · one of two readings recorded this

• grade >=3 constipation

  no effect, p = 0.45

  Constipation | 4 | 454/374 | 1.63[0.46,5.81] | 0.45 | 0.00 | 0.98

  PMID:26399274 · one of two readings recorded this

• grade >=3 cough

  no effect, p = 0.74

  Cough | 2 | 312/303 | 1.32[0.25,6.97] | 0.74 | 0.00 | 0.54

  PMID:26399274 · one of two readings recorded this

• grade >=3 dehydration

  no effect, p = 0.32

  Dehydration | 2 | 94/97 | 3.09[0.33,29.18] | 0.32 | 0.00 | 1.00

  PMID:26399274 · one of two readings recorded this

• grade >=3 diarrhoea

  no effect, p = 0.12

  Diarrhoea | 5 | 590/502 | 1.90[0.84,4.29] | 0.12 | 0.00 | 0.80

  PMID:26399274 · one of two readings recorded this

• grade >=3 dyspnea

  no effect, p = 0.74

  Dyspnea | 4 | 405/349 | 1.14[0.53,2.46] | 0.74 | 16.00 | 0.31

  PMID:26399274 · one of two readings recorded this

• grade >=3 fatigue

  no effect, p = 0.24

  Fatigue | 5 | 548/450 | 1.34[0.82,2.19] | 0.24 | 0.00 | 0.62

  PMID:26399274 · one of two readings recorded this

• grade >=3 headache

  no effect, p = 0.57

  Headache | 2 | 391/372 | 1.45[0.41,5.20] | 0.57 | 8.00 | 0.30

  PMID:26399274 · one of two readings recorded this

• grade >=3 increased ALT

  no effect, p = 0.94

  Increased ALT | 3 | 327/310 | 0.95[0.25,3.62] | 0.94 | 42.00 | 0.18

  PMID:26399274 · one of two readings recorded this

• grade >=3 increased AST

  no effect, p = 0.78

  Increased AST | 2 | 312/303 | 1.10[0.56,2.17] | 0.78 | 0.00 | 0.52

  PMID:26399274 · one of two readings recorded this

• grade >=3 leukopenia

  no effect, p = 0.95

  Leukopenia | 4 | 427/380 | 0.99[0.71,1.38] | 0.95 | 0.00 | 0.44

  PMID:26399274 · one of two readings recorded this

• grade >=3 nausea

  no effect, p = 0.71

  Nausea | 6 | 605/509 | 1.17[0.51,2.66] | 0.71 | 10.00 | 0.35

  PMID:26399274 · one of two readings recorded this

• grade >=3 neutropenia

  increases, p = 0.03

  Neutropenia | 7 | 639/577 | 1.14[1.01,1.29] | 0.03 | 0.00 | 0.46

  PMID:26399274 · one of two readings recorded this

• grade >=3 peripheral edema

  no effect, p = 0.89

  Peripheral edema | 3 | 327/310 | 1.10[0.28,4.42] | 0.89 | 0.00 | 0.73

  PMID:26399274 · one of two readings recorded this

• grade >=3 pulmonary embolism

  no effect, p = 0.98

  Pulmonary embolism | 2 | 93/46 | 1.02[0.29,3.54] | 0.98 | 0.00 | 0.50

  PMID:26399274 · one of two readings recorded this

• grade >=3 thrombocytopenia

  no effect, p = 0.06

  Thrombocytopenia | 4 | 442/387 | 1.26[0.99,1.60] | 0.06 | 0.00 | 0.88

  PMID:26399274 · one of two readings recorded this

• grade >=3 vomiting

  no effect, p = 0.36

  Vomiting | 6 | 605/509 | 1.43[0.66,3.09] | 0.36 | 0.00 | 0.89

  PMID:26399274 · one of two readings recorded this

• median OS

  Gemcitabine/Carboplatin | 62 | 53.0 (26–80) | NA | 7.7 | 3.6

  PMID:26399274 · one of two readings recorded this

• median OS

  Gemcitabine/Carboplatin | 258 | 54.0 (NA) | NA | 11.1 | 4.1

  PMID:26399274 · one of two readings recorded this

• median OS

  Gemcitabine/Carboplatin | 390 | NA | 8.9 | 4.9

  PMID:26399274 · one of two readings recorded this

• median OS

  Gemcitabine/Cisplatin | 39 | 58.0 (29–73) | NA | 8.5 | 4.3

  PMID:26399274 · one of two readings recorded this

• median OS

  O'Shaughnessy, 201120 | II | Breast cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Carboplatin; | 61 | 100 | 56.0 (34–76) | NA | 12.3 | 5.9

  PMID:26399274 · one of two readings recorded this

• median OS

  O'Shaughnessy, 201423 | III | Breast cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Carboplatin; | 261 | 100 | 53.0 (NA) | NA | 11.8 | 5.1

  PMID:26399274 · one of two readings recorded this

• median OS

  Spigel, 201321 | III | Lung cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Carboplatin; | 390 | NA | Total: 66.0 (21–86) | NA | 8.9 | 4.8

  PMID:26399274 · one of two readings recorded this

• median OS

  Novello, 201417 | II | Lung cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Cisplatin; | 80 | 24.4 | 59.0 (37–73) | NA | 12 | 5.7

  PMID:26399274 · one of two readings recorded this

• median OS

  Ledermann, 201418 | II | Ovarian cancer | Olaparib 400 mg (BRCA mutation); | 74 | 100 | 57.5 (38–89) | 74 | 34.9 | 11.2

  PMID:26399274 · one of two readings recorded this

• median OS

  Olaparib 400mg (BRCA wild-type); | 57 | 62.0 (21–80) | 0 | 24.5 | 7.4

  PMID:26399274 · one of two readings recorded this

• median OS

  Oza, 201512 | II | Ovarian cancer | Olaparib (200mg) + paclitaxel/carboplatin, Olaparib (400mg); | 81 | 100 | 59.0 (27–78) | 20 | 33.8 | 12.2

  PMID:26399274 · one of two readings recorded this

• median OS

  Paclitaxel/carboplatin | 81 | 62.0 (31–79) | 21 | 37.6 | 9.6

  PMID:26399274 · one of two readings recorded this

• median OS

  Placebo (BRCA mutation); | 62 | 55.0 (33–84) | 62 | 31.9 | 4.3

  PMID:26399274 · one of two readings recorded this

• median OS

  Placebo (BRCA wild-type) | 61 | 63.0 (49–79) | 0 | 26.2 | 5.5

  PMID:26399274 · one of two readings recorded this

• median PFS

  Cyclophosphamide | 38 | NA | NA | NA | 2.3

  PMID:26399274 · one of two readings recorded this

• median PFS

  Gemcitabine/Carboplatin | 62 | 53.0 (26–80) | NA | 7.7 | 3.6

  PMID:26399274 · one of two readings recorded this

• median PFS

  Gemcitabine/Carboplatin | 258 | 54.0 (NA) | NA | 11.1 | 4.1

  PMID:26399274 · one of two readings recorded this

• median PFS

  Gemcitabine/Carboplatin | 390 | NA | 8.9 | 4.9

  PMID:26399274 · one of two readings recorded this

• median PFS

  Gemcitabine/Cisplatin | 39 | 58.0 (29–73) | NA | 8.5 | 4.3

  PMID:26399274 · one of two readings recorded this

• median PFS

  O'Shaughnessy, 201120 | II | Breast cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Carboplatin; | 61 | 100 | 56.0 (34–76) | NA | 12.3 | 5.9

  PMID:26399274 · one of two readings recorded this

• median PFS

  O'Shaughnessy, 201423 | III | Breast cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Carboplatin; | 261 | 100 | 53.0 (NA) | NA | 11.8 | 5.1

  PMID:26399274 · one of two readings recorded this

• median PFS

  Spigel, 201321 | III | Lung cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Carboplatin; | 390 | NA | Total: 66.0 (21–86) | NA | 8.9 | 4.8

  PMID:26399274 · one of two readings recorded this

• median PFS

  Novello, 201417 | II | Lung cancer | Iniparib (5.6 mg/kg) +Gemcitabine/Cisplatin; | 80 | 24.4 | 59.0 (37–73) | NA | 12 | 5.7

  PMID:26399274 · one of two readings recorded this

• median PFS

  Kaye, 201219 | II | Ovarian cancer | Olaparib (200 mg); | 32 | 100 | 58.5 (45–77) | 32 | NA | 6.5

  PMID:26399274 · one of two readings recorded this

• median PFS

  Olaparib (400 mg); | 32 | 53.5 (35–76) | 32 | NA | 8.8

  PMID:26399274 · one of two readings recorded this

• median PFS

  Ledermann, 201418 | II | Ovarian cancer | Olaparib 400 mg (BRCA mutation); | 74 | 100 | 57.5 (38–89) | 74 | 34.9 | 11.2

  PMID:26399274 · one of two readings recorded this

• median PFS

  Olaparib 400mg (BRCA wild-type); | 57 | 62.0 (21–80) | 0 | 24.5 | 7.4

  PMID:26399274 · one of two readings recorded this

• median PFS

  Oza, 201512 | II | Ovarian cancer | Olaparib (200mg) + paclitaxel/carboplatin, Olaparib (400mg); | 81 | 100 | 59.0 (27–78) | 20 | 33.8 | 12.2

  PMID:26399274 · one of two readings recorded this

• median PFS

  Paclitaxel/carboplatin | 81 | 62.0 (31–79) | 21 | 37.6 | 9.6

  PMID:26399274 · one of two readings recorded this

• median PFS

  Placebo | 33 | 53.0 (43–81) | 33 | NA | 7.1

  PMID:26399274 · one of two readings recorded this

• median PFS

  Placebo (BRCA mutation); | 62 | 55.0 (33–84) | 62 | 31.9 | 4.3

  PMID:26399274 · one of two readings recorded this

• median PFS

  Placebo (BRCA wild-type) | 61 | 63.0 (49–79) | 0 | 26.2 | 5.5

  PMID:26399274 · one of two readings recorded this

• median PFS

  Kummar, 201516 | II | Ovarian cancer, and others | Veliparib (60 mg) +cyclophosphamide; | 37 | NA | NA | NA | NA | 2.1

  PMID:26399274 · one of two readings recorded this

• overall survival, overall population

  no effect

  overall population (HR, 0.92; 95% CI, 0.79–1.08)

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  Iniparib | 417,20,21,23 | 0.83(0.68,1.02) | 51.10% | 0.105 | 417,20,21,23 | 0.86(0.67,1.10) | 63.00% | 0.044

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  Olaparib | 315,18,19 | 0.50(0.32,0.80) | 68.90% | 0.040 | 315,18,19 | 0.99(0.78,1.25) | 0.00% | 0.542

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  BRCA mutation | 315,18,19 | 0.32(0.11,0.94) | 85.60% | 0.001 | 315,18,19 | 0.83(0.57,1.23) | 0.00% | 0.604

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  BRCA status unknown or non-mutation | 617,18,20,21,23,25 | 0.78(0.65,0.95) | 49.90% | 0.076 | 517,18,20,21,23 | 0.89(0.73,1.09) | 50.80% | 0.087

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  Breast cancer | 220,23 | 0.72(0.56,0.94) | 33.70% | 0.219 | 220,23 | 0.74(0.49,1.12) | 62.90% | 0.100

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  Lung cancer | 217,21 | 0.98(0.83,1.15) | 0.00% | 0.672 | 217,21 | 1.00(0.76,1.31) | 35.10% | 0.214

  PMID:26399274 · one of two readings recorded this

• overall survival

  no effect

  Ovarican cancer | 315,18,19 | 0.50(0.32,0.80) | 68.90% | 0.040 | 315,18,19 | 0.99(0.78,1.25) | 0.00% | 0.542

  PMID:26399274 · one of two readings recorded this

• progression-free survival, overall population

  increases

  Hazard ratio (HR), 0.67; 95% confidence interval (CI), 0.50–0.90

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  no effect

  Iniparib | 417,20,21,23 | 0.83(0.68,1.02) | 51.10% | 0.105 | 417,20,21,23 | 0.86(0.67,1.10) | 63.00% | 0.044

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  increases

  Olaparib | 315,18,19 | 0.50(0.32,0.80) | 68.90% | 0.040 | 315,18,19 | 0.99(0.78,1.25) | 0.00% | 0.542

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  increases

  BRCA mutation | 315,18,19 | 0.32(0.11,0.94) | 85.60% | 0.001 | 315,18,19 | 0.83(0.57,1.23) | 0.00% | 0.604

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  increases

  BRCA status unknown or non-mutation | 617,18,20,21,23,25 | 0.78(0.65,0.95) | 49.90% | 0.076 | 517,18,20,21,23 | 0.89(0.73,1.09) | 50.80% | 0.087

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  increases

  Breast cancer | 220,23 | 0.72(0.56,0.94) | 33.70% | 0.219 | 220,23 | 0.74(0.49,1.12) | 62.90% | 0.100

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  no effect

  Lung cancer | 217,21 | 0.98(0.83,1.15) | 0.00% | 0.672 | 217,21 | 1.00(0.76,1.31) | 35.10% | 0.214

  PMID:26399274 · one of two readings recorded this

• progression-free survival

  increases

  Ovarican cancer | 315,18,19 | 0.50(0.32,0.80) | 68.90% | 0.040 | 315,18,19 | 0.99(0.78,1.25) | 0.00% | 0.542

  PMID:26399274 · one of two readings recorded this

• publication bias Egger test, overall survival

  no effect, p = 0.251

  OS: t = −1.30, P = 0.251

  PMID:26399274 · one of two readings recorded this

• publication bias Egger test, progression-free survival

  no effect, p = 0.271

  PFS: t = −1.24, P = 0.271

  PMID:26399274 · one of two readings recorded this

• 18F-FTT AUC in spine, median difference before and after treatment

  no effect, p = 0.7, n = 11

  -3 g/mL · min and 13 g/mL · min [P = .70] for iniparib

  PMID:27841728 · one of two readings recorded this

• 18F-FTT AUC in spine, median difference before and after treatment

  decreases, p = 0.0001, n = 14

  median difference before and after treatment and interquartile range [IQR]: -17 g/mL· min and 10 g/mL · min, respectively [P = .0001], for olaparib

  PMID:27841728 · one of two readings recorded this

• 18F-FTT tumour uptake in subjects with measurable tumors

  increases

  Among five subjects with measurable tumors, increased 18F-FTT uptake was seen in one subject with pancreatic adenocarcinoma and another with liver cancer

  PMID:27841728 · one of two readings recorded this

• estimated effective dose of 18F-FTT in humans

  The effective dose was estimated at 6.9 mSv for a 370-MBq 18F-FTT dose in humans

  PMID:27841728 · one of two readings recorded this

• organs with highest 18F-FTT uptake in humans

  In humans, the organs with the highest uptake on images were the spleen and pancreas

  PMID:27841728 · one of two readings recorded this

• association of PARP expression with triple-negative breast cancer

  increases, p = 0.04

  triple-negative breast cancer (TNBC; RR, 1.81; 95% CI, 1.04-3.17; P = 0.04)

  PMID:28212434 · one of two readings recorded this

• disease-free survival

  decreases, p = 0.03

  a HR of 3.08 (95% CI, 1.14-8.29, P = 0.03) for disease-free survival

  PMID:28212434 · one of two readings recorded this

• higher nuclear grade

  increases, p = 0.008

  higher nuclear grade (RR, 1.51; 95% CI, 1.12-2.04; P = 0.008)

  PMID:28212434 · one of two readings recorded this

• overall survival

  decreases, p = 0.005

  a HR of 1.82 (95% CI, 1.20-2.76; P = 0.005) for overall survival

  PMID:28212434 · one of two readings recorded this

• all-grade constipation

  no effect, p = 0.21

  1.20 (95% CI: 0.88-1.80; P=0.21)

  PMID:30271116 · one of two readings recorded this

• all-grade diarrhea

  increases, p = 0.044

  1.20 (95% CI: 1.01-1.44; P=0.044)

  PMID:30271116 · one of two readings recorded this

• all-grade nausea

  increases, p = 0.001

  2.00 (95% CI: 1.79-2.24; P<0.001)

  PMID:30271116 · one of two readings recorded this

• all-grade vomiting

  increases, p = 0.001

  2.12 (95% CI: 1.75-2.58; P<0.001)

  PMID:30271116 · one of two readings recorded this

• high-grade constipation

  no effect, p = 0.87

  0.92 (95% CI: 0.34-2.49, P=0.87)

  PMID:30271116 · one of two readings recorded this

• high-grade diarrhea

  no effect, p = 0.23

  0.56 (95% CI: 0.22-1.43; P=0.23)

  PMID:30271116 · one of two readings recorded this

• high-grade nausea

  increases, p = 0.005

  3.74 (95% CI: 1.50-9.36; P=0.005)

  PMID:30271116 · one of two readings recorded this

• high-grade vomiting

  increases, p = 0.02

  2.81 (95% CI: 1.17-6.74; P=0.02)

  PMID:30271116 · one of two readings recorded this

• summary incidence of all-grade constipation

  constipation 25.3% (95% CI, 17.9%-34.5%)

  PMID:30271116 · one of two readings recorded this

• summary incidence of all-grade diarrhea

  diarrhea 25.3% (95% CI, 21.2%-29.8%)

  PMID:30271116 · one of two readings recorded this

• summary incidence of all-grade nausea

  nausea 68.8% (95% CI, 63.5%-73.6%)

  PMID:30271116 · one of two readings recorded this

• summary incidence of all-grade vomiting

  vomiting 36.2% (95% CI, 30.9%-41.8%)

  PMID:30271116 · one of two readings recorded this

• all grade adverse events

  no effect, p = 0.16

  did not significantly increase the risk of all grade adverse events (AEs) (RR = 1.04, p = 0.16)

  PMID:32622363 · one of two readings recorded this

• grade 3 or higher adverse events

  increases, p = 0.002

  the incidence of grade 3 or higher AEs was increased (RR = 1.87, p = 0.002)

  PMID:32622363 · one of two readings recorded this

• overall survival

  increases, p = 0.001

  HR, 0.79, 95% CI 0.65-0.94, p < 0.001

  PMID:32622363 · one of two readings recorded this

• progression-free survival

  increases, p = 0.001

  HR 0.44, 95% CI 0.34-0.53, p < 0.001

  PMID:32622363 · one of two readings recorded this

• progression-free survival

  increases, p = 0.001

  In the BRCA 1/2 mutation patients, the HR of PFS was 0.29 (p < 0.001)

  PMID:32622363 · one of two readings recorded this

• progression-free survival

  increases, p = 0.001

  The HR of PFS was 0.40 (p < 0.001) in the homologous recombination deficiency (HRD) mutation patients

  PMID:32622363 · one of two readings recorded this

• progression-free survival

  increases, p = 0.001

  the HR was 0.51 (p < 0.001) in the no BRCA 1/2 mutation patients

  PMID:32622363 · one of two readings recorded this

• progression-free survival

  increases, p = 0.001

  while the HR was 0.80 (p < 0.001) in the no HRD mutation patients

  PMID:32622363 · one of two readings recorded this

• Creatine kinase, change

  p = 0.002

  P 24 | 98.88(− 127.87, −71.90)a | 153.74(− 181.98, − 123.28)a | 0.002c

  PMID:32778175 · one of two readings recorded this

• Creatine kinase, change

  p = 0.079

  P 48 | 81.21(− 135.65, − 28.77)a | 138.17(− 193.11, − 81.02)a | 0.079

  PMID:32778175 · one of two readings recorded this

• Creatine kinase, within-group change

  increases, p = 0.01

  CK increased significantly in both groups after 24-h (p < 0.01) and at 48-h (p < 0.01)

  PMID:32778175 · one of two readings recorded this

• Extensor peak torque, change

  no effect, p = 0.211

  P 24 | −19.68(5.66, 39.06)b | −39.35(18.89, 53.91)b | 0.211

  PMID:32778175 · one of two readings recorded this

• Extensor peak torque, change

  no effect, p = 0.477

  P 48 | −13.41(−2.73, 34.91) | −25.25(2.56, 42.04)a | 0.477

  PMID:32778175 · one of two readings recorded this

• Extensor total work, change

  no effect, p = 0.281

  P 24 | − 73.46(−2.21, 153.12) | − 146.49(62.84, 225.76)b | 0.281

  PMID:32778175 · one of two readings recorded this

• Extensor total work, change

  no effect, p = 0.372

  P 48 | − 58.1(−18.04, 138.23) | − 117.49(33.36, 197.24)b | 0.372

  PMID:32778175 · one of two readings recorded this

• Extensor total work, within-group change

  decreases, p = 0.01

  ETW decreased significantly in PLAC after 24-h (p < 0.01) and 48-h (p < 0.01) but not in DRIB (p > 0.05)

  PMID:32778175 · one of two readings recorded this

• Flexor peak torque, change

  no effect, p = 0.323

  P 24 | 3.71(−11.18, 5.36) | −4.78(− 4.77, 12.57) | 0.323

  PMID:32778175 · one of two readings recorded this

• Flexor peak torque, change

  no effect, p = 0.303

  P 48 | 3.16(−10.80, 6.07) | −5.68(− 4.05, 13.65) | 0.303

  PMID:32778175 · one of two readings recorded this

• Flexor total work, change

  no effect, p = 0.515

  P 24 | 18.67(−72.34, 29.61) | −13.14(−37.36, 69.56) | 0.515

  PMID:32778175 · one of two readings recorded this

• Flexor total work, change

  no effect, p = 0.557

  P 48 | 8.95(− 59.53, 36.26) | − 18.74(− 28.53, 71.93) | 0.557

  PMID:32778175 · one of two readings recorded this

• isokinetic knee flexor and extensor peak torque and total work, IsoMed 2000 at 60 deg/s

  no effect, no significant differences between groups at any time-point

  Not recorded as a finding: no outcome node for isokinetic strength (isometric-peak-force is a different contrast); the sentence also names no compound

  No significant differences were found between groups at any time-points (p > 0.05).

  PMID:32778175 · both readings recorded this

• Lactate dehydrogenase, change

  p = 0.005

  P 24 | 49.17(−98.68, 5.17) | 114.97 (− 172.08, − 63.16)a | 0.005c

  PMID:32778175 · one of two readings recorded this

• Lactate dehydrogenase, change

  p = 0.001

  P 48 | 34.01(−73.42, 10.21) | 162.59(− 209.09, − 121.38)a | < 0.001c

  PMID:32778175 · one of two readings recorded this

• Lactate dehydrogenase, within-group change

  increases, p = 0.01

  LDH increased significantly in PLAC after 24-h (p < 0.01) and 48-h (p < 0.01) but not in DRIB (p > 0.05)

  PMID:32778175 · one of two readings recorded this

• Malondialdehyde, change

  p = 0.029

  P 24 | 1.37(− 3.98, 0.2) | 3.75(−1.33, 0.78)a | 0.029b

  PMID:32778175 · one of two readings recorded this

• Malondialdehyde, change

  p = 0.001

  P 48 | −0.25(− 5.36, − 0.98) | 2.87(− 3.41, − 1.19)a | < 0.001c

  PMID:32778175 · one of two readings recorded this

• Malondialdehyde, within-group change

  increases, p = 0.01

  MDA increased significantly in PLAC after 24-h (p < 0.01) and 48-h (p < 0.01) but not in DRIB (p > 0.05)

  PMID:32778175 · one of two readings recorded this

• Muscle soreness VAS, first exercise session, baseline

  no effect, p = 0.187

  Baseline | 1.5(0.7) | 1.8(0.4) | 0.187

  PMID:32778175 · one of two readings recorded this

• Muscle soreness VAS, first exercise session

  no effect, p = 0.417

  P 24 | 5.4(1.6) | 6.0(1.9) | 0.417

  PMID:32778175 · one of two readings recorded this

• Muscle soreness VAS, first exercise session

  no effect, p = 0.977

  P 48 | 5.3(1.6) | 5.3(2.5) | 0.977

  PMID:32778175 · one of two readings recorded this

• Muscle soreness VAS, second exercise session

  decreases, p = 0.01

  muscle soreness of DRIB was significantly lower than that of PLAC (p < 0.01)

  PMID:32778175 · one of two readings recorded this

• Muscle soreness VAS, second versus first exercise session

  decreases, p = 0.01

  was significantly lower after 24-h and 48-h in the second exercise session than in the first exercise session (p < 0.01)

  PMID:32778175 · one of two readings recorded this

• Myoglobin, change

  p = 0.006

  P 24 | 50.66(− 113.81, − 55.37)a | 86.44(− 54.14, − 15.61)a | 0.006c

  PMID:32778175 · one of two readings recorded this

• Myoglobin, change

  p = 0.23

  P 48 | 16.45(− 124.11, −62.82)a | 29.85(−60.99, − 20.58)a | 0.230

  PMID:32778175 · one of two readings recorded this

• serum creatine kinase, enzymatic kinetic kit, 24 h and 48 h after exercise

  CK significantly higher in PLAC than DRIB at 24 h, not at 48 h

  Not recorded as a finding: mixed timepoints: the between-group difference is significant at 24 h and not at 48 h in the one sentence, so no single overall direction can be anchored

  CK increased significantly in both groups after 24-h (p < 0.01) and at 48-h (p < 0.01); CK was significantly higher in PLAC than in DRIB after 24-h (p < 0.01) but not at 48-h (p > 0.05).

  PMID:32778175 · one of two readings recorded this

• serum creatine kinase, enzymatic kinetic kit

  decreases, lower with D-ribose at 24 h, not different at 48 h

  Not recorded as a finding: mixed timepoints in one sentence: significantly higher in placebo at 24 h but not at 48 h, so no single final-timepoint contrast to record

  CK increased significantly in both groups after 24-h (p < 0.01) and at 48-h (p < 0.01); CK was significantly higher in PLAC than in DRIB after 24-h (p < 0.01) but not at 48-h (p > 0.05).

  PMID:32778175 · one of two readings recorded this

• serum lactate dehydrogenase and myoglobin, enzymatic kit and ELISA

  decreases, LDH higher in placebo at 24 h and 48 h

  Not recorded as a finding: no_outcome_node: no LDH or myoglobin node

  LDH increased significantly in PLAC after 24-h (p < 0.01) and 48-h (p < 0.01) but not in DRIB (p > 0.05); LDH was significantly higher in PLAC than in DRIB after 24-h (p < 0.01) and 48-h (p < 0.01).

  PMID:32778175 · one of two readings recorded this

• serum lactate dehydrogenase, enzymatic kinetic kit

  decreases, LDH significantly higher in PLAC than DRIB at 24 h and 48 h

  Not recorded as a finding: no outcome node for lactate dehydrogenase

  LDH increased significantly in PLAC after 24-h (p < 0.01) and 48-h (p < 0.01) but not in DRIB (p > 0.05); LDH was significantly higher in PLAC than in DRIB after 24-h (p < 0.01) and 48-h (p < 0.01).

  PMID:32778175 · one of two readings recorded this

• serum malondialdehyde, commercial enzymatic kinetic kit

  decreases, MDA higher in placebo than D-ribose at 24 h and 48 h

  Not recorded as a finding: instrument_not_stated: malondialdehyde node requires TBARS or HPLC assay; the paper names only a commercial enzymatic kinetic kit

  MDA was significantly higher in PLAC than in DRIB after 24-h (p < 0.05) and 48-h (p < 0.01).

  PMID:32778175 · one of two readings recorded this

• serum myoglobin, ELISA

  decreases, MB significantly higher in PLAC than DRIB at 24 h

  Not recorded as a finding: no outcome node for myoglobin; difference only at 24 h

  MB in both groups increased significantly after 24-h (p < 0.01), and then decreased significantly after 48-h (p < 0.01), but was significantly higher at 48-h than before exercise (p < 0.01); MB was significantly higher in PLAC than in DRIB after 24-h (p < 0.01).

  PMID:32778175 · one of two readings recorded this

• Superoxide dismutase, change

  no effect, p = 0.932

  P 24 | 11.91(−17.92, − 4.8)a | 11.6(− 40.12, − 15.25)a | 0.932

  PMID:32778175 · one of two readings recorded this

• Superoxide dismutase, change

  no effect, p = 0.077

  P 48 | 28.23(− 19.09, − 5.32)a | 16.66(−30.3, − 4.22)a | 0.077

  PMID:32778175 · one of two readings recorded this

• Total antioxidant capacity, change

  no effect, p = 0.157

  P 24 | 21.48(−30.16, − 12.06)a | 14.97(−23.49, − 10.48)a | 0.157

  PMID:32778175 · one of two readings recorded this

• Total antioxidant capacity, change

  no effect, p = 0.248

  P 48 | 17.36(−24.87, − 5.89)a | 13.11(− 20.34, − 6.7)a | 0.248

  PMID:32778175 · one of two readings recorded this

The whole record — 423 rows